These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 26473951)

  • 1. Knockout Serum Replacement Promotes Cell Survival by Preventing BIM from Inducing Mitochondrial Cytochrome C Release.
    Ishii Y; Nhiayi MK; Tse E; Cheng J; Massimino M; Durden DL; Vigneri P; Wang JY
    PLoS One; 2015; 10(10):e0140585. PubMed ID: 26473951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds.
    Aichberger KJ; Mayerhofer M; Krauth MT; Vales A; Kondo R; Derdak S; Pickl WF; Selzer E; Deininger M; Druker BJ; Sillaber C; Esterbauer H; Valent P
    Cancer Res; 2005 Oct; 65(20):9436-44. PubMed ID: 16230407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GILZ inhibits the mTORC2/AKT pathway in BCR-ABL(+) cells.
    Joha S; Nugues AL; Hétuin D; Berthon C; Dezitter X; Dauphin V; Mahon FX; Roche-Lestienne C; Preudhomme C; Quesnel B; Idziorek T
    Oncogene; 2012 Mar; 31(11):1419-30. PubMed ID: 21804606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib and nilotinib induce apoptosis of chronic myeloid leukemia cells through a Bim-dependant pathway modulated by cytokines.
    Belloc F; Moreau-Gaudry F; Uhalde M; Cazalis L; Jeanneteau M; Lacombe F; Praloran V; Mahon FX
    Cancer Biol Ther; 2007 Jun; 6(6):912-9. PubMed ID: 17538248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.
    Kuroda J; Puthalakath H; Cragg MS; Kelly PN; Bouillet P; Huang DC; Kimura S; Ottmann OG; Druker BJ; Villunger A; Roberts AW; Strasser A
    Proc Natl Acad Sci U S A; 2006 Oct; 103(40):14907-12. PubMed ID: 16997913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The BIM deletion polymorphism: A paradigm of a permissive interaction between germline and acquired TKI resistance factors in chronic myeloid leukemia.
    Ko TK; Chin HS; Chuah CT; Huang JW; Ng KP; Khaw SL; Huang DC; Ong ST
    Oncotarget; 2016 Jan; 7(3):2721-33. PubMed ID: 26517680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.
    Lee J; Shen P; Zhang G; Wu X; Zhang X
    Biomed Pharmacother; 2013 Mar; 67(2):157-63. PubMed ID: 23201011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors.
    Kiyota M; Kuroda J; Yamamoto-Sugitani M; Shimura Y; Nakayama R; Nagoshi H; Mizutani S; Chinen Y; Sasaki N; Sakamoto N; Kobayashi T; Matsumoto Y; Horiike S; Taniwaki M
    Apoptosis; 2013 Nov; 18(11):1437-1446. PubMed ID: 23851982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.
    Dai Y; Rahmani M; Corey SJ; Dent P; Grant S
    J Biol Chem; 2004 Aug; 279(33):34227-39. PubMed ID: 15175350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single nucleotide polymorphism in cBIM is associated with a slower achievement of major molecular response in chronic myeloid leukaemia treated with imatinib.
    Augis V; Airiau K; Josselin M; Turcq B; Mahon FX; Belloc F
    PLoS One; 2013; 8(11):e78582. PubMed ID: 24223824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.
    Reddiconto G; Toto C; Palamà I; De Leo S; de Luca E; De Matteis S; Dini L; Passerini CG; Di Renzo N; Maffia M; Coluccia AM
    Blood; 2012 Mar; 119(10):2335-45. PubMed ID: 22262776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. H2AX phosphorylation regulated by p38 is involved in Bim expression and apoptosis in chronic myelogenous leukemia cells induced by imatinib.
    Dong Y; Xiong M; Duan L; Liu Z; Niu T; Luo Y; Wu X; Xu C; Lu C
    Apoptosis; 2014 Aug; 19(8):1281-92. PubMed ID: 24830786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
    Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia.
    San José-Eneriz E; Agirre X; Jiménez-Velasco A; Cordeu L; Martín V; Arqueros V; Gárate L; Fresquet V; Cervantes F; Martínez-Climent JA; Heiniger A; Torres A; Prósper F; Roman-Gomez J
    Eur J Cancer; 2009 Jul; 45(10):1877-89. PubMed ID: 19403302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
    O'Hare T; Pollock R; Stoffregen EP; Keats JA; Abdullah OM; Moseson EM; Rivera VM; Tang H; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Shakespeare WC; Dalgarno D; Clackson T; Sawyer TK; Deininger MW; Druker BJ
    Blood; 2004 Oct; 104(8):2532-9. PubMed ID: 15256422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
    Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A
    Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
    Lu T; Cao J; Zou F; Li X; Wang A; Wang W; Liang H; Liu Q; Hu C; Chen C; Hu Z; Wang W; Li L; Ge J; Shen Y; Ren T; Liu J; Xia R; Liu Q
    Eur J Pharmacol; 2021 Apr; 897():173944. PubMed ID: 33581133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825.
    Nguyen TK; Rahmani M; Harada H; Dent P; Grant S
    Blood; 2007 May; 109(9):4006-15. PubMed ID: 17218385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The roles of epigenetic modifications of proapoptotic BID and BIM genes in imatinib-resistant chronic myeloid leukemia cells.
    Bozkurt S; Özkan T; Özmen F; Baran Y; Sunguroğlu A; Kansu E
    Hematology; 2013 Jul; 18(4):217-23. PubMed ID: 23394612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.